| Identification | Back Directory | [Name]
Trimazosin | [CAS]
35795-16-5 | [Synonyms]
C005185
Cp 19,106
Cp-19,106
Trimazosin
2-hydroxy-2-methylpropyl 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate
2-Hydroxy-2-methylpropyl 4-(4-amino-6,7,8-trimethoxy-2-quinqzolinyl)-1-piperazinecar boxylate
4-(4-Amino-6,7,8-trimethoxyquinazolin-2-yl)-1-piperazinecarboxylic acid 2-hydroxy-2-methylpropyl ester
4-(4-Amino-6,7,8-trimethoxy-2-quinazolinyl)-1-piperazinecarboxylic acid, 2-hydroxy-2- methylpropyl ester
1-Piperazinecarboxylic acid, 4-(4-amino-6,7,8-trimethoxy-2-quinazolinyl)-, 2-hydroxy-2-methylpropyl ester | [EINECS(EC#)]
252-732-7 | [Molecular Formula]
C20H29N5O6 | [MDL Number]
MFCD00865900 | [MOL File]
35795-16-5.mol | [Molecular Weight]
435.47 |
| Hazard Information | Back Directory | [Uses]
Antihypertensive. | [Definition]
ChEBI: Trimazosin is a N-arylpiperazine. | [in vivo]
Trimazosin (10–30 mg/kg; i.h.; once) produces graded decreases in blood pressure[3]. | Animal Model: | Conscious spontaneously hypertensive rats (SHR)[3] | | Dosage: | 10–30 mg/kg | | Administration: | Subcutaneous administration, once | | Result: | Produced graded decreases in blood pressure. |
| [IC 50]
α1-adrenergic receptor |
|
|